H.C. Wainwright reiterated its Buy rating and $80.00 price target for Corcept Therapeutics (NASDAQ:CORT), highlighting the company's consistent growth in Korlym sales over the past eight quarters ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

H.C. Wainwright initiated coverage of Vertical Aerospace (EVTL) with a Buy rating and $12 price target The company specializes in designing ...

Fintel reports that on February 6, 2025, HC Wainwright & Co. initiated coverage of Harrow (NasdaqGM:HROW) with a Buy ...

On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data, this ...

HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($2.18) per share for the year, up from their prior forecast of ($2.19). HC Wainwright has a “Neutral” rating ...

HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $2.45 per share for the quarter, up from their previous forecast of $2.35.

On Wednesday, H.C. Wainwright reaffirmed a Buy rating on shares of TG Therapeutics (NASDAQ:TGTX) shares with a steady price target of $55.00. The firm's analyst highlighted the company's strong ...

On Monday, H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for ADC Therapeutics (NYSE:ADCT) stock, representing significant upside from the current price of $2.02. According to ...

On Monday, H.C. Wainwright adjusted its outlook on Eton Pharmaceuticals (NASDAQ:ETON), raising the price target to $17.00 from the previous $15.00 while maintaining a Buy rating on the company's ...